DAVPX
Price
$36.26
Change
-$1.10 (-2.94%)
Updated
Dec 18 closing price
VTSMX
Price
$141.24
Change
-$4.58 (-3.14%)
Updated
Dec 18 closing price
Ad is loading...

DAVPX vs VTSMX

Header iconDAVPX vs VTSMX Comparison
Open Charts DAVPX vs VTSMXBanner chart's image
Davenport Core Leaders Fund
Price$36.26
Change-$1.10 (-2.94%)
VolumeN/A
CapitalizationN/A
Vanguard Total Stock Mkt Idx I
Price$141.24
Change-$4.58 (-3.14%)
VolumeN/A
CapitalizationN/A
DAVPX vs VTSMX Comparison Chart
Loading...
View a ticker or compare two or three
VS
DAVPX vs. VTSMX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DAVPX is a Buy and VTSMX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VTSMX has more cash in the bank: 1.84T vs. DAVPX (1.13B). VTSMX pays higher dividends than DAVPX: VTSMX (1.26) vs DAVPX (0.28). DAVPX was incepted earlier than VTSMX: DAVPX (27 years) vs VTSMX (33 years). DAVPX is a more actively managed with annual turnover of: 19.00 vs. VTSMX (2.00). VTSMX has a lower initial minimum investment than DAVPX: VTSMX (3000) vs DAVPX (5000). VTSMX annual gain was more profitable for investors over the last year : 26.90 vs. DAVPX (19.38). VTSMX return over 5 years is better than : 84.16 vs. DAVPX (41.11).
DAVPXVTSMXDAVPX / VTSMX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence27 years33 years-
Gain YTD18.41826.35270%
Front LoadN/AN/A-
Min. Initial Investment50003000167%
Min. Initial Investment IRAN/AN/A-
Net Assets1.13B1.84T0%
Annual Yield % from dividends0.281.2622%
Returns for 1 year19.3826.9072%
Returns for 3 years13.0727.8847%
Returns for 5 years41.1184.1649%
Returns for 10 years97.66192.0451%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TIVC0.230.01
+3.77%
Tivic Health Systems
THRD11.350.23
+2.07%
Third Harmonic Bio
VRNT29.420.36
+1.24%
Verint Systems
PEN247.550.31
+0.13%
Penumbra
CNTX1.29-0.07
-5.15%
Context Therapeutics